Research programme: asthma therapy - OSI Pharmaceuticals
Alternative Names: Asthma therapy research programme - OSI PharmaceuticalsLatest Information Update: 30 Jun 2006
At a glance
- Originator OSI Pharmaceuticals
- Class
- Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 30 Jun 2006 No development reported - Preclinical for Asthma in USA (unspecified route)
- 26 Jun 2002 This programme is still in active development
- 25 Feb 2000 Preclinical development for Asthma in USA (Unknown route)